Grant: Project Grant
University of Calgary
$100,000.00
Mobilizing anti-tumor microglia/macrophages to improve the prognosis of glioblastoma: Bench to clinical trial and back
FY 2016-17
Summary
Glioblastoma (GBM) is a highly malignant brain tumor where less than five percent of patients survive beyond five years. This dismal prognosis calls for fresh ideas and new treatment regimens. Recently, brain tumor initiating cells (BTICs), also called brain tumor stem cells, were discovered and they exploit the immune system (macrophages and microglia) by suppressing their activity or by eliciting growth factors to sustain brain tumor growth. An important and novel approach would thus be to rejuvenate or mobilize the compromised macrophages and microglia to contain BTICs. The collaboration between Drs. John Kelly (neurosurgeon/glioma biologist), Jeff Dunn (magnetic resonance imaging, MRI) and Wee Yong (neuroimmunologist) has uncovered generic medications with the capacity to stimulate macrophages/microglia. These include an anti-fungal medication, amphotericin B, and vitamin B3 (niacin). Amphotericin B is poorly tolerated in humans so the group has developed niacin further. Impressively, the group has found that in mice with brain tumors, treatment with niacin mobilizes the compromised immune cells, reduces tumor volume as detected through MRI and histology, and significantly prolongs the lifespan of mice. Remarkably, the life-extending impact of niacin exceeds that of the current front line therapy for GBM, temozolomide, and the combination of niacin and temozolomide has even better outcomes. To bring the laboratory findings to the clinic, the team now includes two neuro-oncologists, Paula de Robles and Gloria Urgoiti. Together, the team will determine how niacin stimulates immune cells to contain brain tumor growth, further boosts the capacity to stimulate immune cells, and conduct a Phase I/2 trial of niacin as an immune stimulator in GBM patients. Collectively, this team seeks to uncover new insights of GBM and translate therapeutics from the bench to bedside to mobilize the normally protective immune system to improve the prognosis of GBM.
Department
Program
Project Grant
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
366554
Name
Yong Voon W
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Project Grant Competition
Projecttitle
Mobilizing anti-tumor microglia/macrophages to improve the prognosis of glioblastoma: Bench to clinical trial and back
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Bench To Bedside; Brain Tumor; Clinical Trial; Compromised Immunity; Glioma; Macrophages; Microglia; Mri; Neuroimmunology; Niacin
Abstract
Glioblastoma (GBM) is a highly malignant brain tumor where less than five percent of patients survive beyond five years. This dismal prognosis calls for fresh ideas and new treatment regimens. Recently, brain tumor initiating cells (BTICs), also called brain tumor stem cells, were discovered and they exploit the immune system (macrophages and microglia) by suppressing their activity or by eliciting growth factors to sustain brain tumor growth. An important and novel approach would thus be to rejuvenate or mobilize the compromised macrophages and microglia to contain BTICs. The collaboration between Drs. John Kelly (neurosurgeon/glioma biologist), Jeff Dunn (magnetic resonance imaging, MRI) and Wee Yong (neuroimmunologist) has uncovered generic medications with the capacity to stimulate macrophages/microglia. These include an anti-fungal medication, amphotericin B, and vitamin B3 (niacin). Amphotericin B is poorly tolerated in humans so the group has developed niacin further. Impressively, the group has found that in mice with brain tumors, treatment with niacin mobilizes the compromised immune cells, reduces tumor volume as detected through MRI and histology, and significantly prolongs the lifespan of mice. Remarkably, the life-extending impact of niacin exceeds that of the current front line therapy for GBM, temozolomide, and the combination of niacin and temozolomide has even better outcomes. To bring the laboratory findings to the clinic, the team now includes two neuro-oncologists, Paula de Robles and Gloria Urgoiti. Together, the team will determine how niacin stimulates immune cells to contain brain tumor growth, further boosts the capacity to stimulate immune cells, and conduct a Phase I/2 trial of niacin as an immune stimulator in GBM patients. Collectively, this team seeks to uncover new insights of GBM and translate therapeutics from the bench to bedside to mobilize the normally protective immune system to improve the prognosis of GBM.
Competitiondate
201611
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yong, Voon W
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~